Exciting news from our youngest spinoff company: Engimmune Therapeutics completed a CHF 15.5 million seed financing round to boost R&D of novel T-​cell receptor (TCR)-​based therapeutics. Proceeds from the financing will be used to further build Engimmune’s pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-​certified manufacturing, clinical development, and regulatory affairs.

The startup community is hit particularly hard by the global COVID-​19 pandemic. The D-​BSSE spinoff deepCDR Biologics is making the best out of this extraordinary situation - and realises that the pandemic provides the perfect platform to showcase the deepCDR technology and antibody discovery and development. Interview with the co-​founder Derek Mason.

The Botnar Research Centre for Child Health (BRCCH) announces its first four multi-​investigator projects and thus the start of its research activities. D-​BSSE professor Randall Platt will have the lead of a project which aims to develop a CRISPR-​based technology involving engineered bacteria which are capable of sensing, remembering, and reporting on the environment within the gut.

Join D-​BSSE Professor Sai Reddy at the Festival of Biologics on 15-​17 October 2019 in Basel. He will be a speaker at the European Antibody Congress discussing antibody engineering in mammalian cells by genome editing. The conference unites four congresses under one roof. Free and discount passes are available for conference delegates and for visitors to the exhibition.